{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:03:31Z","timestamp":1784887411883,"version":"3.55.0"},"reference-count":20,"publisher":"American Animal Hospital Association","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Most urinary bladder (UB) tumors are malignant, and transitional cell carcinoma (TCC) is the most common neoplasm affecting the UB in dogs. Sorafenib may be a potential therapeutic agent for canine TCC. A 12 yr old spayed female Maltese dog weighing 3.6 kg and with a history of hematuria was referred for a suspected UB tumor. Abdominal ultrasonography revealed a UB mass attached to the cranioventral wall. The remaining abdominal examinations, including that of the lymph nodes, were unremarkable. Ultrasound-guided traumatic catheterization of the UB mass was performed, and the cytological evaluation of the UB mass indicated TCC. Excision was performed by partial cystectomy, and histopathology confirmed TCC, although the tumor had infiltrated the surgical margins. A chemosensitivity assay was conducted using tissue from the excised tumor. Sorafenib tosylate, a tyrosine kinase inhibitor, showed the greatest effect in the chemosensitivity assay. Therefore, adjuvant chemotherapy with sorafenib tosylate and piroxicam was administered postoperatively. The dog lived without any clinical signs, including hematuria or tumor relapse, for more than 2 yr after the surgery. This is the first report of successful long-term management of TCC with sorafenib tosylate in a dog.<\/jats:p>","DOI":"10.5326\/jaaha-ms-7463","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T12:09:09Z","timestamp":1730376549000},"page":"275-279","source":"Crossref","is-referenced-by-count":1,"title":["Successful Management of Incompletely Resected Transitional Cell Carcinoma with Sorafenib Tosylate in a Dog"],"prefix":"10.5326","volume":"60","author":[{"given":"Dongheon","family":"Shin","sequence":"first","affiliation":[{"name":"From the Laboratory of Veterinary Internal Medicine (D.S., C.K., Y.C., T.Y., B.-T.K, H.K.), College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaerin","family":"Kim","sequence":"additional","affiliation":[{"name":"From the Laboratory of Veterinary Internal Medicine (D.S., C.K., Y.C., T.Y., B.-T.K, H.K.), College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeon","family":"Chae","sequence":"additional","affiliation":[{"name":"From the Laboratory of Veterinary Internal Medicine (D.S., C.K., Y.C., T.Y., B.-T.K, H.K.), College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taesik","family":"Yun","sequence":"additional","affiliation":[{"name":"From the Laboratory of Veterinary Internal Medicine (D.S., C.K., Y.C., T.Y., B.-T.K, H.K.), College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-Teck","family":"Kang","sequence":"additional","affiliation":[{"name":"From the Laboratory of Veterinary Internal Medicine (D.S., C.K., Y.C., T.Y., B.-T.K, H.K.), College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Mee","family":"Park","sequence":"additional","affiliation":[{"name":"Laboratory of Veterinary Surgery\/Ophthalmology (K.-M.P), College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakhyun","family":"Kim","sequence":"additional","affiliation":[{"name":"From the Laboratory of Veterinary Internal Medicine (D.S., C.K., Y.C., T.Y., B.-T.K, H.K.), College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3280","reference":[{"key":"i0587-2871-60-6-275-b1","series-title":"J Comp Pathol","first-page":"113","article-title":"Pathology of canine bladder and urethral cancer and correlation with tumour progression and survival","volume":"113","author":"Valli","year":"1995","unstructured":"Valli\n              VE,\n            \n            \n              Norris\n              A,\n            \n            \n              Jacobs\n              RM,\n            \n            \n          \n          Pathology of canine bladder and urethral cancer and correlation with tumour progression and survival. J Comp Pathol1995;113:113\u201330."},{"key":"i0587-2871-60-6-275-b2","series-title":"ILAR J","first-page":"100","article-title":"Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development","volume":"55","author":"Knapp","year":"2014","unstructured":"Knapp\n              DW,\n            \n            \n              Ramos-Vara\n              JA,\n            \n            \n              Moore\n              GE,\n            \n            \n          \n          Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development. ILAR J2014;55:100\u201318."},{"key":"i0587-2871-60-6-275-b3","series-title":"Textbook of Bladder Cancer.","first-page":"171","author":"Knapp","year":"2006","unstructured":"Knapp\n              DW.\n            \n          \n          Animal models: naturally occurring canine urinary bladder cancer. In: LernerSP,SchoenbergMP,SternbergCN, eds. Textbook of Bladder Cancer.1st ed. Oxon: The Taylor and Francis Group; 2006:171\u20135."},{"key":"i0587-2871-60-6-275-b4","series-title":"Withrow and MacEwen\u2019s Small Animal Clinical Oncology.","first-page":"572","author":"Knapp","year":"2013","unstructured":"Knapp\n              DW,\n            \n            \n              McMillan\n              SK.\n            \n          \n          Tumors of the urinary system. In: WithrowSJ,VailDM, eds. Withrow and MacEwen\u2019s Small Animal Clinical Oncology.5th ed. Missouri: Elsevier-Saunders; 2013:572\u201382."},{"key":"i0587-2871-60-6-275-b5","series-title":"J Vet Intern Med","first-page":"136","article-title":"Canine transitional cell carcinoma","volume":"17","author":"Mutsaers","year":"2003","unstructured":"Mutsaers\n              AJ,\n            \n            \n              Widmer\n              WR,\n            \n            \n              Knapp\n              DW.\n            \n          \n          Canine transitional cell carcinoma. J Vet Intern Med2003;17:136\u201344."},{"key":"i0587-2871-60-6-275-b6","series-title":"Companion Animal","first-page":"21","article-title":"Canine transitional cell carcinoma: a review of current paradigms","volume":"21","author":"Serra","year":"2016","unstructured":"Serra\n              JC,\n            \n            \n              Hill\n              T,\n            \n            \n              Lawrence\n              J.\n            \n          \n          Canine transitional cell carcinoma: a review of current paradigms. Companion Animal2016;21:21\u20138."},{"key":"i0587-2871-60-6-275-b7","series-title":"J Vet Med Sci","first-page":"666","article-title":"Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma","volume":"84","author":"Yokota","year":"2022","unstructured":"Yokota\n              S,\n            \n            \n              Yonezawa\n              T,\n            \n            \n              Momoi\n              Y,\n            \n            \n          \n          Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma. J Vet Med Sci2022;84:666-674."},{"key":"i0587-2871-60-6-275-b8","series-title":"J Intern Med","first-page":"114","article-title":"VEGFA and tumour angiogenesis","volume":"273","author":"Claesson-Welsh","year":"2013","unstructured":"Claesson-Welsh\n              L,\n            \n            \n              Welsh\n              M.\n            \n          \n          VEGFA and tumour angiogenesis. J Intern Med2013;273:114\u201327."},{"key":"i0587-2871-60-6-275-b9","series-title":"Annu Rev Med","first-page":"71","article-title":"Platelet-derived growth factor","volume":"38","author":"Ross","year":"1987","unstructured":"Ross\n              R.\n            \n          \n          Platelet-derived growth factor. Annu Rev Med1987;38:71\u20139."},{"key":"i0587-2871-60-6-275-b10","series-title":"Cell Physiol Biochem","first-page":"1751","article-title":"Melatonin synergizes with sorafenib to suppress pancreatic cancer via melatonin receptor and PDGFR-\u03b2\/STAT3 pathway","volume":"47","author":"Fang","year":"2018","unstructured":"Fang\n              Z,\n            \n            \n              Jung\n              KH,\n            \n            \n              Yan\n              HH,\n            \n            \n          \n          Melatonin synergizes with sorafenib to suppress pancreatic cancer via melatonin receptor and PDGFR-\u03b2\/STAT3 pathway. Cell Physiol Biochem2018;47:1751\u201368."},{"key":"i0587-2871-60-6-275-b11","series-title":"BMC Vet Res","first-page":"320","article-title":"Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines","volume":"17","author":"Korec","year":"2021","unstructured":"Korec\n              DI,\n            \n            \n              Louke\n              DS,\n            \n            \n              Breitbach\n              JT,\n            \n            \n          \n          Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines. BMC Vet Res2021;17:320."},{"key":"i0587-2871-60-6-275-b12","series-title":"TNM Classification of Tumours in Domestic Animals.","author":"Owen","unstructured":"Owen\n              LN\n            \n          , World Health Organization. TNM Classification of Tumours in Domestic Animals.Geneva (Switzerland): World Health Organization."},{"key":"i0587-2871-60-6-275-b13","series-title":"J Am Anim Hosp Assoc","first-page":"165","article-title":"Clinical assessment of a chemosensitivity assay as a treatment planning tool for dogs with cancer","volume":"37","author":"Henry","year":"2001","unstructured":"Henry\n              CJ,\n            \n            \n              McCaw\n              DL,\n            \n            \n              Buss\n              MS,\n            \n            \n          \n          Clinical assessment of a chemosensitivity assay as a treatment planning tool for dogs with cancer. J Am Anim Hosp Assoc2001;37:165\u201371."},{"key":"i0587-2871-60-6-275-b14","series-title":"J Vet Intern Med","first-page":"145","article-title":"Canine bladder and urethral tumors: a retrospective study of 115 cases (1980-1985)","volume":"6","author":"Norris","year":"1992","unstructured":"Norris\n              AM,\n            \n            \n              Laing\n              EJ,\n            \n            \n              Valli\n              VE,\n            \n            \n          \n          Canine bladder and urethral tumors: a retrospective study of 115 cases (1980-1985). J Vet Intern Med1992;6:145\u201353."},{"key":"i0587-2871-60-6-275-b15","series-title":"Vet J","first-page":"217","article-title":"Management of transitional cell carcinoma of the urinary bladder in dogs: a review","volume":"205","author":"Fulkerson","year":"2015","unstructured":"Fulkerson\n              CM,\n            \n            \n              Knapp\n              DW.\n            \n          \n          Management of transitional cell carcinoma of the urinary bladder in dogs: a review. Vet J2015;205:217\u201325."},{"key":"i0587-2871-60-6-275-b16","series-title":"J Am Anim Hosp Assoc","first-page":"243","article-title":"Use of toceranib phosphate in the treatment of canine bladder tumors: 37 cases","volume":"55","author":"Gustafson","year":"2019","unstructured":"Gustafson\n              TL,\n            \n            \n              Biller\n              B.\n            \n          \n          Use of toceranib phosphate in the treatment of canine bladder tumors: 37 cases. J Am Anim Hosp Assoc2019;55:243\u20138."},{"key":"i0587-2871-60-6-275-b17","series-title":"Cancer Chemother Pharmacol","first-page":"535","article-title":"Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials","volume":"61","author":"Takimoto","year":"2008","unstructured":"Takimoto\n              CH,\n            \n            \n              Awada\n              A.\n            \n          \n          Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemother Pharmacol2008;61:535\u201348."},{"key":"i0587-2871-60-6-275-b18","series-title":"Vet Comp Oncol","first-page":"1417","article-title":"Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder","volume":"15","author":"Marvel","year":"2017","unstructured":"Marvel\n              SJ,\n            \n            \n              S\u00e9guin\n              B,\n            \n            \n              Dailey\n              DD,\n            \n            \n          \n          Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder. Vet Comp Oncol2017;15:1417\u201327."},{"key":"i0587-2871-60-6-275-b19","series-title":"Clin Cancer Res","first-page":"906","article-title":"Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma","volume":"9","author":"Henry","year":"2003","unstructured":"Henry\n              CJ,\n            \n            \n              McCaw\n              DL,\n            \n            \n              Turnquist\n              SE,\n            \n            \n          \n          Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res2003;9:906\u201311."},{"key":"i0587-2871-60-6-275-b20","series-title":"Vet Q","first-page":"153","article-title":"Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib)","volume":"41","author":"Kim","year":"2021","unstructured":"Kim\n              JH,\n            \n            \n              Ahn\n              DH,\n            \n            \n              Moon\n              JS,\n            \n            \n          \n          Longitudinal assessment of B-RAF V595E levels in the peripheral cell-free tumor DNA of a 10-year-old spayed female Korean Jindo dog with unresectable metastatic urethral transitional cell carcinoma for monitoring the treatment response to a RAF inhibitor (sorafenib). Vet Q2021;41:153\u201362."}],"container-title":["Journal of the American Animal Hospital Association"],"original-title":[],"link":[{"URL":"https:\/\/jaaha.kglmeridian.com\/view\/journals\/aaha\/60\/6\/article-p275.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jaaha\/article-pdf\/60\/6\/275\/3451718\/i1547-3317-60-6-275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jaaha.kglmeridian.com\/downloadpdf\/journals\/aaha\/60\/6\/article-p275.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jaaha.kglmeridian.com\/downloadpdf\/journals\/aaha\/60\/6\/article-p275.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T16:05:43Z","timestamp":1763741143000},"score":1,"resource":{"primary":{"URL":"https:\/\/jaaha.kglmeridian.com\/view\/journals\/aaha\/60\/6\/article-p275.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":20,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.5326\/jaaha-ms-7463","relation":{},"ISSN":["1547-3317","0587-2871"],"issn-type":[{"value":"1547-3317","type":"electronic"},{"value":"0587-2871","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}